<DOC>
	<DOCNO>NCT00961233</DOCNO>
	<brief_summary>The purpose study conduct clinical trial two formulation budesonide ( nebulized/swallowed versus viscous/swallowed ) patient EoE determine medication contact time distribution esophagus relate treatment response . The investigator also determine systemic absorption topical steroid . The investigator hypothesize tissue symptom response correlate esophageal medication contact time distribution , significant systemic absorption see .</brief_summary>
	<brief_title>Topical Budesonide Treatment Eosinophilic Esophagitis ( EoE )</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>New diagnosis eosinophilic esophagitis ( per 2007 consensus guideline ) Age &lt; 18 Inability read understand English Pregnant nurse woman Previous allergic reaction steroid medication Current use systemic steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>eosinophilic esophagitis</keyword>
</DOC>